U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07161999) titled 'Study of COYA 302 for the Treatment of ALS' on Aug. 31.
Brief Summary: The ALSTARS trial will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS). COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. It is comprised of low dose interleukin-2 (LD IL-2) and CTLA4-Ig (a biosimilar candidate for abatacept). Participants will be ...